Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Oct 29;13(11):3877.
doi: 10.3390/nu13113877.

A Protective Role for Arachidonic Acid Metabolites against Advanced Colorectal Adenoma in a Phase III Trial of Selenium

Affiliations
Clinical Trial

A Protective Role for Arachidonic Acid Metabolites against Advanced Colorectal Adenoma in a Phase III Trial of Selenium

Jessica A Martinez et al. Nutrients. .

Abstract

Oxylipins derived from arachidonic acid (ARA) have been implicated in the development of colorectal adenomas and colorectal cancer. The primary purpose of this work was to determine the relationship between plasma levels of oxylipins and colorectal adenoma characteristics at study entry, as well as with the development of a new adenoma during follow-up within a Phase III adenoma prevention clinical trial with selenium (Sel). Secondarily, we sought to determine whether the selenium intervention influenced plasma oxylipin levels. Four oxylipins were quantified in stored plasma samples from a subset of Sel study subjects (n = 256) at baseline and at 12-months. There were significantly lower odds of an advanced adenoma at baseline with higher prostaglandin E2 (PGE2), with an OR (95% CI) of 0.55 (0.33-0.92), and with 5-hydroxyeicosatetraenoic acid (5-HETE) ((0.53 (0.33-0.94)); and of a large adenoma with higher PGE2 ((0.52 (0.31-0.87)). In contrast, no associations were observed between any oxylipin and the development of a new adenoma during follow-up. Selenium supplementation was associated with a significantly smaller increase in 5-HETE after 12 months compared to the placebo, though no other results were statistically significant. The ARA-derived oxylipins may have a role in the progression of non-advanced adenoma to advanced, but not with the development of a new adenoma.

Keywords: ARA; arachidonic acid; colon cancer; colorectal adenoma; colorectal neoplasia; oxylipins; selenium.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to declare.

Figures

Figure 1
Figure 1
Arachidonic Acid metabolism via COX-2, CYP450, 5-LOX and 12-LOX. ARA metabolism via COX-2, CYP450, 5-LOX and 12-LOX produces PGE2, 20-HETE, 5-HETE, and 12-HETE respectively. Only those oxylipins quantified on our platform are illustrated here. Abbreviations: COX-2: cyclooxygenase-2; CYP450: cytochrome P450; 5-LOX: 5-lipoxygenase; 12-LOX: 12-lipoxygenase; PGE2: prostaglandin E2; 5-HETE: 5-hydroxyeicosatetraenoic acid; 12-HETE: 12-hydroxyeicosatetraenoic acid.

Similar articles

Cited by

References

    1. Nakanishi M., Rosenberg D.W. Multifaceted roles of PGE2 in inflammation and cancer. Semin Immunopathol. 2013;35:123–137. doi: 10.1007/s00281-012-0342-8. - DOI - PMC - PubMed
    1. Feng Y.L., Shu L., Zheng P.F., Zhang X.Y., Si C.J., Yu X.L., Gao W., Zhang L. Dietary patterns and colorectal cancer risk: A meta-analysis. Eur. J. Cancer Prev. 2017;26:201–211. doi: 10.1097/CEJ.0000000000000245. - DOI - PubMed
    1. Randi G., Edefonti V., Ferraroni M., La Vecchia C., Decarli A. Dietary patterns and the risk of colorectal cancer and adenomas. Nutr. Rev. 2010;68:389–408. doi: 10.1111/j.1753-4887.2010.00299.x. - DOI - PubMed
    1. Wang D., DuBois R.N. An inflammatory mediator, prostaglandin E2, in colorectal cancer. Cancer J. 2013;19:502–510. doi: 10.1097/PPO.0000000000000003. - DOI - PMC - PubMed
    1. Shrubsole M.J., Cai Q., Wen W., Milne G., Smalley W.E., Chen Z., Ness R.M., Zheng W. Urinary prostaglandin E2 metabolite and risk for colorectal adenoma. Cancer Prev. Res. 2012;5:336–342. doi: 10.1158/1940-6207.CAPR-11-0426. - DOI - PMC - PubMed

Publication types